CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,210,602 | -30.9% | 2,529,116 | +0.6% | 1.48% | -22.2% |
| Q2 2023 | $79,917,390 | +30.3% | 2,513,916 | 0.0% | 1.90% | +29.9% |
| Q1 2023 | $61,314,411 | -22.4% | 2,513,916 | +0.3% | 1.46% | -23.1% |
| Q4 2022 | $79,053,875 | +11.9% | 2,506,464 | +0.3% | 1.90% | +4.3% |
| Q3 2022 | $70,626,000 | +51.2% | 2,499,148 | +41.4% | 1.82% | +34.1% |
| Q2 2022 | $46,723,000 | -22.6% | 1,767,141 | +2.5% | 1.36% | -10.5% |
| Q1 2022 | $60,334,000 | +12.9% | 1,723,341 | +4.5% | 1.52% | +23.0% |
| Q4 2021 | $53,442,000 | +13.2% | 1,648,435 | +3.0% | 1.24% | +24.4% |
| Q3 2021 | $47,217,000 | +81.2% | 1,600,589 | +57.4% | 0.99% | +92.8% |
| Q2 2021 | $26,054,000 | +88.8% | 1,016,945 | +1.2% | 0.52% | +71.1% |
| Q1 2021 | $13,800,000 | -16.7% | 1,005,100 | +0.6% | 0.30% | -14.2% |
| Q4 2020 | $16,563,000 | – | 999,000 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |